Hybridize Therapeutics
Manufacturing · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Rijnsburgerweg 10, Leiden, South Holland...Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Hybridize Therapeutics
Hybridize Therapeutics specializes in developing kidney-targeted RNA-based therapies aimed at protecting patients from acute and chronic kidney diseases. Their innovative approach focuses on high target specificity to prevent the progression to end-stage renal disease (ESRD). The company emerged as a spin-off from the Leiden University Medical Center, leveraging extensive research in nephrology and RNA medicine. Their primary clients include patients suffering from kidney diseases and healthcare providers seeking advanced therapeutic options.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hybridize Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Hybridize Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Hybridize Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Hybridize Therapeutics recently announced quarterly report
Check out if Hybridize Therapeutics is spiking on competitors!
Hybridize Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Hybridize Therapeutics
Click to see if Hybridize Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Hybridize Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Hybridize Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hybridize Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hybridize Therapeutics.
Hybridize Therapeutics Tech Stack
A closer look at the technologies used by Hybridize Therapeutics
See more technologies
Hybridize Therapeutics News & Media
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hybridize Therapeutics
Sign Up For FreeTo access detailed company insights
Hybridize Therapeutics specializes in developing kidney-targeted RNA-based therapies aimed at protecting patients from acute and chronic kidney diseases. Their innovative approach focuses on high target specificity to prevent the progression to end-stage renal disease (ESRD). The company emerged as a spin-off from the Leiden University Medical Cent... Read More
